

## Office of Pharmacy Services PRESCRIBER'S STATEMENT OF MEDICAL NECESSITY (SMN)

Synagis® (palivizumab)

(Only for FFS participants- Incomplete forms will be returned)

Tel: 1-800-932-3918 Fax: 1-866-440-<u>9345</u>

	Patient	t Information	
Patient location: home h Patient Name: Fel#: () Gestational age:weeks	nospital Clinic Weight at birth: days Most Current Weigh	Request is for $\square$ 1st RS  MA ID#:  Kg Date of Birth:  Kg Date	SV season
	Prescrib	er Information	
Prescriber's Name:		Specialty:	Telephone:NPI#:
A copy of Patient's NICU dischar	rge summary must accompar	ny this PA request.	
List all <b>previously</b> administered Sy	/nagis injections (if any) with d	dates given: (max 5 dos	ses)
Current Request for Synagis (palifor refills - the office is to fax Pati the attached Synagis Service PA fo	ient's most current body weigh		I weight measurements to the State using
Pediatrics (AAP) guideline	es):		the 2014 American Academy of CLD) or congenital heart disease (CHD)
□ > 21 percent of all that apply): □ Acyanotic he □ Required □ Curroll □ Cyanotic heat □ Pedi □ Moderate to so □ Other □ Infant < 12 months of secretions from the upper □ Infant < 12 months wit □ Infant < 2 yrs. of age word □ chronic cortic □ Infant < 2 yrs. of age word □ following: □ previous hore □ weight for 1 □ Infants < 2y/o who are □ Infants < 2y/o who are □ Infants < 2y/o who corporeal membrane oxygout □ Other □ Other □ Infants < 2y/o who corporeal membrane oxygout □ Other □ Infants < 2y/o who conducts □ Infants ○ 2y/o who conducts	age born with hemodynamical art disease uires a cardiac surgical procedurently receiving medication to a rt disease latric cardiologist has been consevere pulmonary hypertension age born with neuromuscular dairway.  th Cystic Fibrosis and clinical dairway.  th Cystic Fibrosis that previous obspitalization for pulmonary expected tomography that persists when the 10 <sup>th</sup> percest profoundly immunocompromed a cardiac transplant during Resention require prophylaxis and genation requiring a post-op dostons, for which prophylaxis may	ure control heart failure. List medicusulted. List the pediatric cardion.  disease or a congenital heart and evidence of CLD or nutritional or the previous 6 months continuity diuretic therapy usly received Synagis therapy facerbation in the first year of liwhen stable or abnormalities or entile based on WHO growth continuity dividence of the stable	cations  complete the disease (CHD) characterized by (check cations  complete the disease (CHD) characterized by (check cations)  complete the disease (CHD) characterized by (check check characterized by (check check characterized by (check check check characterized by (check check characterized by (check check check characterized by (check check characterized by (check check check characterized by (check check chec
Consultation with the child's cardio  Original Prescriber's signature:			
Original Prescriber's signature:		_	

Fax#: \_\_\_\_/\_\_\_

Pharmacy Phone #: \_\_\_\_\_/\_\_\_\_